Bristol-Myers Squibb(US:BMY) ZACKS·2024-09-05 22:51Company Performance - Bristol Myers Squibb (BMY) stock closed at $49.80, reflecting a -0.32% change from the previous day, underperforming the S&P 500's daily loss of 0.3% [1] - The stock has increased by 7.44% over the past month, outperforming the Medical sector's gain of 4.56% and the S&P 500's gain of 3.42% [1] Upcoming Earnings - The upcoming earnings release is highly anticipated, with projected earnings per share (EPS) of $1.58, indicating a 21% decrease from the same quarter last year [1] - Revenue is expected to be $11.29 billion, which is a 2.97% increase from the prior-year quarter [1] - For the full year, earnings are projected at $0.77 per share and revenue at $46.82 billion, representing changes of -89.75% and +4.04% respectively from the prior year [1] Analyst Estimates - Recent modifications to analyst estimates indicate changing business trends, with positive revisions reflecting analysts' confidence in the company's performance [2] - The Zacks Rank system, which incorporates estimate changes, currently ranks Bristol Myers Squibb at 3 (Hold) [2] - Over the last 30 days, the Zacks Consensus EPS estimate has increased by 0.2% [2] Valuation Metrics - Bristol Myers Squibb has a Forward P/E ratio of 64.74, which is significantly higher than the industry's average Forward P/E of 23.2 [3] - The company's PEG ratio stands at 12.95, compared to the Medical - Biomedical and Genetics industry's average PEG ratio of 2.15 [3] - The Medical - Biomedical and Genetics industry has a Zacks Industry Rank of 84, placing it in the top 34% of over 250 industries [3]